Answers are grounded in this paper and cite their sources.
Research reveals m6A dynamics drive kinase reprogramming in breast cancer, suggesting new therapeutic targets.
Endocrine therapy resistance (ETR) in estrogen receptor-positive breast cancer arises through multiple adaptive mechanisms, with kinase reprogramming representing a central driver of therapeutic escape. N6-methyladenosine (m6A), the most abundant internal RNA modification, has emerged as a key regulator of RNA fate, yet its role in restructuring kinase networks during ETR is unclear. Using GLORI sequencing, a single-nucleotide-resolution method for stoichiometric m6A quantification, we profiled parental, tamoxifen and exemestane resistant MCF7 derivatives. Tamoxifen-resistant cells exhibited ∼2,600 m6A sites with canonical DRACH motifs with widespread hyper- and hypomethylation across transcripts encoding MAPK regulators, receptor tyrosine kinases, and cell-cycle-associated kinases. Multi-omic integration including RNA-seq and quantitative proteomics indicate differentially methylated kinase mRNAs gained stability, enhanced translational efficiency and increased protein output, establishing an m6A-dependent mechanism of kinase reprogramming. Resistant cells also displayed selective upregulation of m6A-associated RNA-binding proteins, including YTHDF1 and IGF2BP2, consistent with a remodeled post-transcriptional landscape. Together, our findings uncover a previously underappreciated epitranscriptomic layer integrating quantitative m6A dynamics and RNA-binding protein shifts that drives kinase reprogramming and promotes ETR in breast cancer. Citation Format: Attila Szenasi, Enakshi Sivasudhan, Santiago Haase, Austin Whitman, Kate D. Meyer, Philip M. Spanheimer. m6A-mediated control of kinase reprogramming in endocrine therapy-resistant breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1794.
No takes yet. Share an insight, caveat, or question.
Szénási et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: